Next Article in Journal
New and Emerging Viruses of Blueberry and Cranberry
Next Article in Special Issue
Host Cell Factors in Filovirus Entry: Novel Players, New Insights
Previous Article in Journal
Arenaviruses and Lethal Mutagenesis. Prospects for New Ribavirin-based Interventions
Previous Article in Special Issue
Niemann-Pick C1 (NPC1)/NPC1-like1 Chimeras Define Sequences Critical for NPC1’s Function as a Filovirus Entry Receptor
Article Menu

Export Article

Open AccessArticle
Viruses 2012, 4(11), 2806-2830; doi:10.3390/v4112806

Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections

Sarepta Therapeutics, Bothell, Washington 98021, USA
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA
Author to whom correspondence should be addressed.
Received: 3 September 2012 / Revised: 2 October 2012 / Accepted: 2 October 2012 / Published: 6 November 2012
(This article belongs to the Special Issue Advances in Filovirus Research 2012)
View Full-Text   |   Download PDF [458 KB, uploaded 12 May 2015]   |  


There are no currently approved treatments for filovirus infections. In this study we report the discovery process which led to the development of antisense Phosphorodiamidate Morpholino Oligomers (PMOs) AVI-6002 (composed of AVI-7357 and AVI-7539) and AVI-6003 (composed of AVI-7287 and AVI-7288) targeting Ebola virus and Marburg virus respectively. The discovery process involved identification of optimal transcript binding sites for PMO based RNA-therapeutics followed by screening for effective viral gene target in mouse and guinea pig models utilizing adapted viral isolates. An evolution of chemical modifications were tested, beginning with simple Phosphorodiamidate Morpholino Oligomers (PMO) transitioning to cell penetrating peptide conjugated PMOs (PPMO) and ending with PMOplus containing a limited number of positively charged linkages in the PMO structure. The initial lead compounds were combinations of two agents targeting separate genes. In the final analysis, a single agent for treatment of each virus was selected, AVI-7537 targeting the VP24 gene of Ebola virus and AVI-7288 targeting NP of Marburg virus, and are now progressing into late stage clinical development as the optimal therapeutic candidates. View Full-Text
Keywords: Ebola; Marburg; Phosphorodiamidate Morpholino Oligomer; PMOplus; therapeutic; antiviral Ebola; Marburg; Phosphorodiamidate Morpholino Oligomer; PMOplus; therapeutic; antiviral

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Iversen, P.L.; Warren, T.K.; Wells, J.B.; Garza, N.L.; Mourich, D.V.; Welch, L.S.; Panchal, R.G.; Bavari, S. Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses 2012, 4, 2806-2830.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top